Canada Pharmaceutical Market Research on Size, Share, Trends, Segments, Regions & Competition

The Canada Pharmaceutical Market Report Segments the Industry Into by ATC/Therapeutic Class (Alimentary Tract and Metabolism, Cardiovascular System, and More), by Drug Type (Prescription and OTC Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Province.

Canada Pharmaceutical Market Size and Share

Canada Pharmaceutical Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Canada Pharmaceutical Market Analysis by Mordor Intelligence

The Canada pharmaceutical market, valued at USD 34.91 billion in 2025 with an anticipated rise to USD 43.92 billion by 2030, is expanding along a measured 4.70% CAGR that aligns neatly with Ottawa’s explicit goal of reducing supply-chain reliance on foreign active pharmaceutical ingredients. While these headline figures capture the trajectory, executive focus is sharpening on what the new domestic biomanufacturing build-out really signals: capital allocation is quietly shifting from late-stage sales and marketing budgets to early-stage technology transfer and process-validation expertise, indicating that firms expect regulatory certainty around good manufacturing practice to tighten further.

Key Report Takeaways

• The Canada pharmaceutical market size is USD 34.91 billion in 2025 and is forecast to reach USD 43.92 billion by 2030, representing a steady 4.70 % CAGR that is materially underwritten by publicly funded biomanufacturing incentives.

• Ontario remains the single-largest provincial opportunity with 37.8 % market share in 2024, yet Alberta’s compound growth outpaces all peers, confirming that population migration is beginning to redraw commercial call-plan maps.

• Specialty medicines drive a growing share of drug expenditure even as generics account for more than three-quarters of prescriptions, a pattern that signals ongoing margin compression in primary-care portfolios.

• Only 16.1 % of the CAD 5.3 billion (USD 3.98 billion) biologic drug market is served by biosimilars, highlighting an untapped savings pool that could become pivotal if a universal pharmacare bill passes.

• Domestic mRNA manufacturing build-outs, led by a 100 million-dose-per-year facility in Laval, suggest that Canada is positioning itself as a North American hub for advanced-therapy fill-finish capacity.

Segment Analysis

Cardiovascular Dominance Faces Disruption in ATC / Therapeutic Class Segment

Cardiovascular drugs held 14.2% share in 2024, yet the antineoplastic and immunomodulating agents segment is projected to expand at 6.8% CAGR through 2030. A subtle but influential shift is underway: cardiologists are adopting polygenic-risk scoring to stratify statin initiation, effectively redefining “primary prevention” cohorts. That practice could curtail volume growth in lipid-lowering therapy while redirecting developmental capital toward inflammation-modulating cardio-oncology crossovers.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Generic Expansion Challenges Branded Dominance in Drug Type Segment

Branded prescriptions still command 62.5% of market value even though generics make up more than three-quarters of scripts dispensed. Executives note an emerging pattern: pharmacists vested with independent prescriptive authority are increasingly selecting generic molecules as first-line therapy, but retaining branded products for clinically complex cases. This bifurcation suggests that brand equity will depend less on direct-to-consumer advertising and more on differentiated real-world evidence that reinforces therapeutic superiority.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Digital Disruption Accelerates in Distribution Channel Segment

Retail pharmacies captured 72.1% market share in 2024. Yet online pharmacy revenue is forecast at a 7.9% CAGR between 2025 and 2030, a pace underscoring how telemedicine platforms are collapsing the boundary between consultation and fulfillment. One second-order effect: logistics providers are investing in cold-chain micro-warehousing close to urban centers so that temperature-sensitive biologics can meet same-day delivery windows demanded by virtual clinics—an infrastructural tweak with considerable capital-spending implications.

Geography Analysis

Ontario dominates the Canadian pharmaceutical landscape with spending above CAD 11 billion (USD 8.25 billion) a year, half of which is consumed by seniors. Provincial policy makers are reassessing whether income-based deductibles truly deliver equity, as evidence accrues that seniors juggle multiple therapies and therefore face compounding co-payments. If a national pharmacare scheme were to materialize, Ontario’s sizeable private-payer infrastructure might be redeployed toward supplemental benefits, effectively repositioning insurers as service integrators rather than primary drug financiers.

Alberta’s health outlays reached CAD 45 billion (USD 33.75 billion) in 2024, equating to CAD 9,370 (USD 7,028) per capita versus a national average of CAD 9,054 (USD 6,791). Behind the headline, administrators are piloting drug-cost off-ramps that include therapeutic interchange policies and biosimilar switching incentives. Those measures reflect an executive belief that bending the cost curve on pharmaceuticals may buy political latitude to invest in under-resourced rural hospitals—a trade-off that reshapes the strategic sales focus for specialty-care reps.

Quebec distinguishes itself with mandatory drug insurance that splits premium burden between government and citizens, a configuration that expands formulary breadth but caps price escalation via reference pricing. British Columbia’s aggressive biosimilar substitution policy signals a willingness to trade rapid uptake for short-term physician pushback. Manufacturers are thus prioritizing stakeholder-management resources in provinces where policy volatility can swing quarterly revenue run-rates.

Competitive Landscape

A moderately concentrated market features Pfizer, Novartis and Johnson & Johnson alongside domestic champion Apotex. Biosimilar penetration at only 16.1 % underscores white-space potential, but market entry timing must account for upcoming Patented Medicine Prices Review Board (PMPRB) ceiling tightening, which could clip launch-price headroom. Moderna’s 100 million-dose mRNA facility in Laval is already igniting interest from mid-cap biotechs seeking North American fill-finish partners, suggesting that domestic CMO capacity could soon trade at a premium. Meanwhile, private-equity ownership of Apotex unlocks capital for bolt-on acquisitions; early signals indicate a preference for complex-generic assets with vertical formulations expertise, a strategy that aims to mitigate commodity pricing pressure in oral solids.

Canada Pharmaceutical Industry Leaders

  1. Pfizer Inc.

  2. Apotex Inc.

  3. Johnson & Johnson (Janssen)

  4. Novartis AG

  5. F. Hoffmann-La Roche AG

  6. *Disclaimer: Major Players sorted in no particular order
Canada Pharmaceutical Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: Health Canada released the “Pan-Canadian Prescription Drug Data Landscape,” confirming that Canadian list prices rank among the highest in the OECD and introducing draft legislation for a universal pharmacare framework.
  • June 2024: Pfizer Canada announced a CAD 4.9 million (USD 3.68 million) research grant to McMaster University aimed at optimizing multiple-myeloma care pathways.
  • May 2024: The Canadian Generic Pharmaceutical Association initiated a nationwide stakeholder-education campaign titled “Myth vs. Reality,” underscoring the budgetary relief generics generate.

Table of Contents for Canada Pharmaceutical Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population
    • 4.2.2 Growing Burden of Chronic Diseases (Diabetes, Oncology)
    • 4.2.3 Federal Biomanufacturing & Life-Sciences Strategy Incentives
    • 4.2.4 Growing Demand for Innovative Drugs
    • 4.2.5 Expansion of Specialty Pharmacy Networks for High-cost Biologics
    • 4.2.6 Strong Research and Development Capabilities
  • 4.3 Market Restraints
    • 4.3.1 High List Prices of Innovative Medicines
    • 4.3.2 Lengthy Health-Canada Review & Listing Timelines
    • 4.3.3 PMPRB Price Ceiling Tightening
    • 4.3.4 Limited Access to Pharmacy Channel
  • 4.4 Pipeline Analysis
  • 4.5 Statistical Overview
    • 4.5.1 Number of Hospitals
    • 4.5.2 Employment in Pharmacutical Sector
    • 4.5.3 R&D Expenditure
  • 4.6 Epidemiology Data for Key Diseases
  • 4.7 Pharmaceutical Import & Exports
  • 4.8 Porter’s Five Forces
    • 4.8.1 Threat of New Entrants
    • 4.8.2 Bargaining Power of Buyers/Consumers
    • 4.8.3 Bargaining Power of Suppliers
    • 4.8.4 Threat of Substitutes
    • 4.8.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, CAD Bn)

  • 5.1 By ATC / Therapeutic Class
    • 5.1.1 Alimentary Tract & Metabolism
    • 5.1.2 Blood & Blood-forming Organs
    • 5.1.3 Cardiovascular System
    • 5.1.4 Dermatologicals
    • 5.1.5 Genito-Urinary System & Sex Hormones
    • 5.1.6 Systemic Hormonal Preparations
    • 5.1.7 Antiinfectives for Systemic Use
    • 5.1.8 Antineoplastic & Immunomodulating Agents
    • 5.1.9 Musculoskeletal System
    • 5.1.10 Nervous System
    • 5.1.11 Antiparasitic Products, Insecticides & Repellents
    • 5.1.12 Respiratory System
    • 5.1.13 Sensory Organs
    • 5.1.14 Other Therapeutic Classes
  • 5.2 By Drug Type
    • 5.2.1 Prescription
    • 5.2.1.1 Branded
    • 5.2.1.2 Generic
    • 5.2.2 OTC Drugs
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 By Province
    • 5.4.1 Ontario
    • 5.4.2 Quebec
    • 5.4.3 British Columbia
    • 5.4.4 Alberta
    • 5.4.5 Rest of Canada

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Strategic Moves
  • 6.3 Market Share Analysis
  • 6.4 Company Profiles (includes Global level Overview, Market level Overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and Analysis of Recent Developments)
    • 6.4.1 Pfizer Inc.
    • 6.4.2 Apotex Inc.
    • 6.4.3 Johnson & Johnson (Janssen)
    • 6.4.4 Novartis AG
    • 6.4.5 F. Hoffmann-La Roche AG
    • 6.4.6 Merck & Co., Inc.
    • 6.4.7 Abbott Laboratories
    • 6.4.8 Bristol-Myers Squibb Co.
    • 6.4.9 Eli Lilly and Company
    • 6.4.10 AbbVie Inc.
    • 6.4.11 Sanofi S.A.
    • 6.4.12 GlaxoSmithKline plc
    • 6.4.13 Teva
    • 6.4.14 Sandoz
    • 6.4.15 AstraZeneca
    • 6.4.16 Bayer Inc.
    • 6.4.17 Boehringer Ingelheim
    • 6.4.18 Bausch Health Companies Inc.
    • 6.4.19 Takeda Pharmaceutical
    • 6.4.20 Pharmascience Inc.
    • 6.4.21 Knight Therapeutics Inc.
    • 6.4.22 Jazz Pharmaceuticals PLC

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Canada Pharmaceutical Market Report Scope

As per the scope of this report, pharmaceuticals are referred to as medications or medicinal drugs intended to prevent, diagnose, treat, or cure a disease. They may be prescription or non-prescription drugs. The Canadian pharmaceutical market is segmented by ATC/therapeutic class, drug type, distribution channel, and province. By ATC/therapeutics class, the market is segmented by alimentary tract and metabolism, blood and blood-forming organs, cardiovascular system, dermatologicals, genito-urinary system and sex hormones, systemic hormonal preparations, antiinfectives for systemic use, antineoplastic and immunomodulating agents, musculoskeletal system, nervous system, antiparasitic products, insecticides and repellents, respiratory system, sensory organs, and other ATC/therapeutic classes. By drug type, the market is segmented into prescription type and OTC drugs. The prescription type is further bifurcated into branded and generic. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By province, the market is segmented into Ontario, Quebec, British Columbia, Alberta, and the Rest of Canada. The report offers the value (in USD billion) for the above segments.

By ATC / Therapeutic Class Alimentary Tract & Metabolism
Blood & Blood-forming Organs
Cardiovascular System
Dermatologicals
Genito-Urinary System & Sex Hormones
Systemic Hormonal Preparations
Antiinfectives for Systemic Use
Antineoplastic & Immunomodulating Agents
Musculoskeletal System
Nervous System
Antiparasitic Products, Insecticides & Repellents
Respiratory System
Sensory Organs
Other Therapeutic Classes
By Drug Type Prescription Branded
Generic
OTC Drugs
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Province Ontario
Quebec
British Columbia
Alberta
Rest of Canada
By ATC / Therapeutic Class
Alimentary Tract & Metabolism
Blood & Blood-forming Organs
Cardiovascular System
Dermatologicals
Genito-Urinary System & Sex Hormones
Systemic Hormonal Preparations
Antiinfectives for Systemic Use
Antineoplastic & Immunomodulating Agents
Musculoskeletal System
Nervous System
Antiparasitic Products, Insecticides & Repellents
Respiratory System
Sensory Organs
Other Therapeutic Classes
By Drug Type
Prescription Branded
Generic
OTC Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Province
Ontario
Quebec
British Columbia
Alberta
Rest of Canada
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How large is the Canada pharmaceutical market in 2025?

The market size is estimated at USD 34.91 billion for 2025.

What is the projected Canada pharmaceutical market size in 2030?

It is forecast at USD 43.92 billion, underpinned by a 4.70 % CAGR.

Which province commands the largest market share?

Ontario leads with 37.8 % share, driven by population density and healthcare infrastructure.

How significant is the biosimilar segment today?

Biosimilars currently address roughly one-sixth of the biologic market, indicating ample headroom for cost-saving uptake.

Canada Pharmaceutical Market Report Snapshots

Compare market size and growth of Canada Pharmaceutical Market with other markets in Healthcare Industry

Access Report long-arrow-right